Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 417 people across four groups: one group received a placebo (a dummy treatment with no active ingredient), and the other three groups received different doses of an experimental drug called LY2382770 — either 2 mg, 10 mg, or 50 mg. The trial ran for 12 months and was primarily looking at changes in kidney function over time, measured through a blood marker called serum creatinine (a waste product the kidneys filter out — higher levels can suggest the kidneys are working less well). Around 62–66 people in each group completed the full study, with roughly 37–41 in each group not completing it. The reported data shows that for the primary measure — the change in serum creatinine levels from the start to the 12-month mark — all four groups showed a small increase over time. The placebo group's figure was 0.13 (on a mathematical scale used to analyse the data), while the three LY2382770 groups each recorded figures of 0.17–0.18. For the secondary measures, the reported data shows changes in a urine protein ratio (another marker linked to kidney health) were similarly small across all groups: 0.06 for placebo, 0.05 for the 2 mg and 10 mg groups, and −0.01 for the 50 mg group. The rate at which kidney filtration capacity (eGFR — a standard measure of how well kidneys filter the blood) changed per month was reported as −0.37 for placebo, −0.37 for the 2 mg group, −0.56 for the 10 mg group, and −0.40 for the 50 mg group. Drug exposure levels in the blood were also measured and increased with higher doses, though no placebo figure applies for that measure. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Type 1 Diabetes Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have chronic kidney disease that is believed to be caused by Type 1 or Type 2 diabetes
- Your kidney function falls within a specific range, based on blood test results measuring creatinine levels or an estimated kidney function score (confirm with trial site for your exact numbers)
- A urine test shows that your kidneys are leaking a significant amount of protein (confirm with trial site for your exact levels)
- You are already taking a stable dose of a common blood pressure/kidney-protecting medication (ACE inhibitor or ARB), or you are unable to take these types of medications
Who may not be able to join:
- Women who are pregnant, breastfeeding, or who are able to become pregnant
- People who have a long-term inflammatory or autoimmune condition (such as lupus or rheumatoid arthritis)
- People whose kidney disease is caused by something other than diabetes
- People who have received an organ transplant
- People with blood pressure that is too high
- People who have Hepatitis B, Hepatitis C, cirrhosis, or another serious liver condition
- People who have had recent bleeding in their stomach or intestines
- People who had a serious kidney injury in the 3 months before joining the study
- People who had major surgery in the 3 months before joining, or who plan to have major surgery during the study
- People who are living with HIV
- People with an unstable heart condition
- People with a recent cancer diagnosis or a condition that significantly raises the risk of cancer (confirm with trial site)
- People who need to take medications that affect the immune system
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
13 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change in Log Transformed (In) Serum Creatinine From Baseline to 12 Month Endpoint
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.